Top

Journal of Orthopaedic Surgery and Research

Published in:

Open Access 01-12-2015 | Research article

Effect of bisphosphonates in preventing femoral periprosthetic bone resorption after primary cementless total hip arthroplasty: a meta-analysis

Authors: Xinyu Zhao, Dongcai Hu, Jun Qin, Rahul Mohanan, Liaobin Chen

Published in: Journal of Orthopaedic Surgery and Research | Issue 1/2015

Abstract

Background

Bone loss leading to aseptic loosening of the prosthesis and periprosthetic fracture is a mode of failure in cementless total hip arthroplasty (THA). The aim of this meta-analysis was to evaluate the effect of bisphosphonates in preventing femoral periprosthetic bone resorption following primary cementless THA zone by zone.

Method

Clinical randomized controlled trials concerning bisphosphonates application after primary cementless THA published up to October 2014 were retrieved from PubMed, Cochrane library, and Embase databases. The methodological quality of the included studies was assessed by the Physiotherapy Evidence Database (PEDro) scale. Data analysis was performed using StataSE12.0.

Results

Ten randomized controlled trials involving a total of 502 patients were assessed; the bisphosphonates group included 256 patients and the control group included 246 patients. The meta-analysis showed that the bone mineral density (BMD) of most femoral periprosthetic zones in bisphosphonates group was significantly higher than that in the control group at 3 months postoperatively except zone 5 with no significant difference. At 6 and 12 months, the BMD of bisphosphonates group was much higher than that in control group except zone 5, which showed no statistical difference. The BMD of bisphosphonates group was persistently higher than control group in zone 6 and 7 at 5 years postoperatively, while the other zones had no significant difference. Both serum bone alkaline phosphatase and urinary type I collagen N-telopeptide were significantly suppressed by bisphosphonates at 3, 6, and 12 months.

Conclusion

Bisphosphonates seem to decrease early femoral periprosthetic bone resorption after primary cementless THA. Drug efficacy was found to be long-standing in the main load-bearing zones.

Mednick RE, Alvi HM, Krishnan V, Lovecchio F, Manning DW. Factors affecting readmission rates following primary total hip arthroplasty. J Bone Joint Surg Am. 2014;96:1201–9.CrossRefPubMed

Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;89:780–5.CrossRefPubMed

Furnes O, Lie SA, Espehaug B, Vollset SE, Engesaeter LB, Havelin LI. Hip disease and the prognosis of total hip replacements. A review of 53,698 primary total hip replacements reported to the Norwegian Arthroplasty Register 1987–99. J Bone Joint Surg Br. 2001;83:579–86.CrossRefPubMed

Morris CD, Einhorn TA. Bisphosphonates in orthopaedic surgery. J Bone Joint Surg Am. 2005;87:1609–18.CrossRefPubMed

Fokter SK, Komadina R, Repse-Fokter A. Effect of etidronate in preventing periprosthetic bone loss following cemented hip arthroplasty: a randomized, double blind, controlled trial. Wien Klin Wochenschr. 2006;118 Suppl 2:23–8.CrossRefPubMed

Shetty N, Hamer AJ, Stockley I, Eastell R, Willkinson JM. Clinical and radiological outcome of total hip replacement five years after pamidronate therapy. A trial extension. J Bone Joint Surg Br. 2006;88:1309–15.CrossRefPubMed

Tapaninen TS, Venesmaa PK, Jurvelin JS, Miettinen HJ, Kroger HP. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty - a 5-year follow-up of 16 patients. Scand J Surg. 2010;99:32–7.PubMed

Bhandari M, Bajammal S, Guyatt GH, Griffith L, Busse JW, Schunemann H, et al. Effect of bisphosphonates on periprosthetic bone mineral density after total joint arthroplasty. A meta-analysis. J Bone Joint Surg Am. 2005;87:293–301.CrossRefPubMed

Lin T, Yan SG, Cai XZ, Ying ZM. Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials. Osteoporos Int. 2012;23:1823–34.CrossRefPubMed

10.

Gruen TA, McNeice GM, Amstutz HC. “Modes of failure” of cemented stem-type femoral components: a radiographic analysis of loosening. Clin Orthop Relat Res. 1979;141:17–27.PubMed

11.

de Morton NA. The PEDro scale is a valid measure of the methodological quality of clinical trials: a demographic study. Aust J Physiother. 2009;55:129–33.CrossRefPubMed

12.

Iwamoto N, Inaba Y, Kobayashi N, Ishida T, Yukizawa Y, Saito T. A comparison of the effects of alendronate and alfacalcidol on bone mineral density around the femoral implant and in the lumbar spine after total hip arthroplasty. J Bone Joint Surg Am. 2011;93:1203–9.CrossRefPubMed

13.

Skoldenberg OG, Salemyr MO, Boden HS, Ahl TE, Adolphson PY. The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial. J Bone Joint Surg Am. 2011;93:1857–64.CrossRefPubMed

14.

Yamasaki S, Masuhara K, Yamaguchi K, Nakai T, Fuji T, Seino Y. Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty. Osteoporos Int. 2007;18:1009–15.CrossRefPubMed

15.

Yamaguchi K, Masuhara K, Yamasaki S, Fuji T. Efficacy of different dosing schedules of etidronate for stress shielding after cementless total hip arthroplasty. J Orthop Sci. 2005;10:32–6.CrossRefPubMed

16.

Venesmaa PK, Kroger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhav EM. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study. J Bone Miner Res. 2001;16:2126–31.CrossRefPubMed

17.

Trevisan C, Ortolani S, Romano P, Isaia G, Agnese L, Dallari D, et al. Decreased periprosthetic bone loss in patients treated with clodronate: a 1-year randomized controlled study. Calcif Tissue Int. 2010;86:436–46.CrossRefPubMed

18.

Arabmotlagh M, Rittmeister M, Hennigs T. Alendronate prevents femoral periprosthetic bone loss following total hip arthroplasty: prospective randomized double-blind study. J Orthop Res. 2006;24:1336–41.CrossRefPubMed

19.

Arabmotlagh M, Pilz M, Warzecha J, Rauschmann M. Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty. J Orthop Res. 2009;27:183–8.CrossRefPubMed

20.

Hennigs T, Arabmotlagh M, Schwarz A, Zichner L. Dose-dependent prevention of early periprosthetic bone loss by alendronate. Z Orthop Ihre Grenzgeb. 2002;140:42–7.CrossRefPubMed

21.

Muratore M, Quarta E, Quarta L, Calcagnile F, Grimaldi A, Orgiani MA, et al. Ibandronate and cementless total hip arthroplasty: densitometric measurement of periprosthetic bone mass and new therapeutic approach to the prevention of aseptic loosening. Clin Cases Miner Bone Metab. 2012;9:50–5.PubMedCentralPubMed

22.

Dominguez-Bartmess SN, Tandberg D, Cheema AM, Szalay EA. Efficacy of alendronate in the treatment of low bone density in the pediatric and young adult population. J Bone Joint Surg Am. 2012;94:e62.CrossRefPubMed

23.

Friedl G, Radl R, Stihsen C, Rehak P, Aigner R, Windhager R. The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial. J Bone Joint Surg Am. 2009;91:274–81.CrossRefPubMed

24.

Prieto-Alhambra D, Javaid MK, Judge A, Murray D, Carr A, Cooper C, et al. Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study. BMJ. 2011;343:d7222.CrossRefPubMedCentralPubMed

25.

Thillemann TM, Pedersen AB, Mehnert F, Johnsen SP, Soballe K. Postoperative use of bisphosphonates and risk of revision after primary total hip arthroplasty: a nationwide population-based study. Bone. 2010;46:946–51.CrossRefPubMed

26.

Sayyidmousavi A, Bougherara H. Investigation of stress shielding around the Stryker Omnifit and Exeter periprosthetic hip implants using an irreversible thermodynamic-based model. J Biomed Mater Res B Appl Biomater. 2012;100:1416–24.CrossRefPubMed

27.

Boden HS, Skoldenberg OG, Salemyr MO, Lundberg HJ, Adolphson PY. Continuous bone loss around a tapered uncemented femoral stem: a long-term evaluation with DEXA. Acta Orthop. 2006;77:877–85.CrossRefPubMed

28.

Yeung E, Bott PT, Chana R, Jackson MP, Holloway I, Walter WL, et al. Mid-term results of third-generation alumina-on-alumina ceramic bearings in cementless total hip arthroplasty: a ten-year minimum follow-up. J Bone Joint Surg Am. 2012;94:138–44.CrossRefPubMed

29.

Eberhardt C, Habermann B, Muller S, Schwarz M, Bauss F, Kurth AH. The bisphosphonate ibandronate accelerates osseointegration of hydroxyapatite-coated cementless implants in an animal model. J Orthop Sci. 2007;12:61–6.CrossRefPubMed

30.

Colon-Emeric CS. Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis: enough of a good thing. JAMA. 2006;296:2968–9.CrossRefPubMed

Title: Effect of bisphosphonates in preventing femoral periprosthetic bone resorption after primary cementless total hip arthroplasty: a meta-analysis
Authors: Xinyu Zhao
Dongcai Hu
Jun Qin
Rahul Mohanan
Liaobin Chen
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Journal of Orthopaedic Surgery and Research / Issue 1/2015
Electronic ISSN: 1749-799X
DOI: https://doi.org/10.1186/s13018-015-0206-8

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Effect of bisphosphonates in preventing femoral periprosthetic bone resorption after primary cementless total hip arthroplasty: a meta-analysis

Abstract

Background

Method

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2015

The metaphyseal bone defect in distal radius fractures and its implication on trabecular remodeling—a histomorphometric study (case series)

Significant pain reduction and improved functional outcome after surgery for displaced midshaft clavicular fractures

Influence of the image levels of distal femur on the measurement of tibial tubercle-trochlear groove distance—a comparative study

Retraction Note: Pathological dislocation of the hip due to coxotuberculosis in children: a 29-case report

Elcatonin attenuates disuse osteoporosis after fracture fixation of tubular bone in rats

Modified minimally invasive transforaminal lumbar interbody fusion using a trans-multifidus approach: a safe and effective alternative to open-TLIF